000300745 001__ 300745
000300745 005__ 20250504020357.0
000300745 0247_ $$2doi$$a10.1186/s12885-025-14168-y
000300745 0247_ $$2pmid$$apmid:40307814
000300745 0247_ $$2altmetric$$aaltmetric:176601254
000300745 037__ $$aDKFZ-2025-00905
000300745 041__ $$aEnglish
000300745 082__ $$a610
000300745 1001_ $$aStøer, Nathalie C$$b0
000300745 245__ $$aLow-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway.
000300745 260__ $$aLondon$$bBioMed Central$$c2025
000300745 3367_ $$2DRIVER$$aarticle
000300745 3367_ $$2DataCite$$aOutput Types/Journal article
000300745 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746176110_34
000300745 3367_ $$2BibTeX$$aARTICLE
000300745 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300745 3367_ $$00$$2EndNote$$aJournal Article
000300745 500__ $$a#LA:C020#
000300745 520__ $$aAspirin and non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAID) have been associated with improved survival in individuals with epithelial ovarian cancer (EOC); however, findings to date are inconsistent.We conducted a registry-based cohort study evaluating survival following an incident invasive EOC diagnosis including individuals diagnosed between 2004-2018 (n = 4325; n = 2206 deaths; n = 1973 EOC deaths). Evaluated exposures were low-dose aspirin and NA-NSAIDs. Two primary post-diagnosis exposure windows were evaluated: fixed post-diagnostic baseline exposure ≤ 305 days after diagnosis (use, non-use) and updated 'time-varying' exposure (never, past, current use; cumulative defined daily dose (DDD)). Pre-diagnostic exposure (use, non-use) was further evaluated. Multivariable Cox-proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals [95% CIs]. The primary outcome was cause-specific survival. Restricted mean survival time (RMST) in exposure groups was estimated at 5 years following start of follow-up.Baseline post-diagnosis aspirin use was not associated with survival following an EOC diagnosis (e.g., use vs. no use: aspirin, HR = 1.02 [95% CI = 0.84-1.24]). Inverse associations were observed between current aspirin use post-diagnosis and survival in the time-varying exposure models (HR 0.68 [0.57-0.81]), and with higher post-diagnosis cumulative DDD of aspirin. Findings for NA-NSAIDs were less consistent. No associations were observed for pre-diagnostic use. Results for overall survival were similar to those for cause-specific survival. Compared to never use, post-diagnosis low-dose aspirin use was associated with a longer RMST (e.g., ever vs. never use, difference in RMST = 2.67 months).This study provides further evidence of a potential beneficial effect of post-diagnosis low-dose aspirin use for ovarian cancer survival.
000300745 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300745 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300745 650_7 $$2Other$$aAspirin
000300745 650_7 $$2Other$$aNon-aspirin NSAIDs
000300745 650_7 $$2Other$$aOvarian cancer
000300745 650_7 $$2Other$$aSurvival
000300745 650_7 $$0R16CO5Y76E$$2NLM Chemicals$$aAspirin
000300745 650_7 $$2NLM Chemicals$$aAnti-Inflammatory Agents, Non-Steroidal
000300745 650_2 $$2MeSH$$aHumans
000300745 650_2 $$2MeSH$$aFemale
000300745 650_2 $$2MeSH$$aAspirin: administration & dosage
000300745 650_2 $$2MeSH$$aAspirin: therapeutic use
000300745 650_2 $$2MeSH$$aAnti-Inflammatory Agents, Non-Steroidal: administration & dosage
000300745 650_2 $$2MeSH$$aAnti-Inflammatory Agents, Non-Steroidal: therapeutic use
000300745 650_2 $$2MeSH$$aCarcinoma, Ovarian Epithelial: mortality
000300745 650_2 $$2MeSH$$aCarcinoma, Ovarian Epithelial: drug therapy
000300745 650_2 $$2MeSH$$aRegistries: statistics & numerical data
000300745 650_2 $$2MeSH$$aNorway: epidemiology
000300745 650_2 $$2MeSH$$aMiddle Aged
000300745 650_2 $$2MeSH$$aAged
000300745 650_2 $$2MeSH$$aOvarian Neoplasms: mortality
000300745 650_2 $$2MeSH$$aOvarian Neoplasms: drug therapy
000300745 650_2 $$2MeSH$$aCohort Studies
000300745 650_2 $$2MeSH$$aAdult
000300745 650_2 $$2MeSH$$aProportional Hazards Models
000300745 7001_ $$aBotteri, Edoardo$$b1
000300745 7001_ $$aLindemann, Kristina$$b2
000300745 7001_ $$aLangseth, Hilde$$b3
000300745 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b4$$eLast author$$udkfz
000300745 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-025-14168-y$$gVol. 25, no. 1, p. 807$$n1$$p807$$tBMC cancer$$v25$$x1471-2407$$y2025
000300745 909CO $$ooai:inrepo02.dkfz.de:300745$$pVDB
000300745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300745 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300745 9141_ $$y2025
000300745 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:34:06Z
000300745 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:34:06Z
000300745 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-04-10T15:34:06Z
000300745 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-20
000300745 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-20
000300745 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300745 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300745 980__ $$ajournal
000300745 980__ $$aVDB
000300745 980__ $$aI:(DE-He78)C020-20160331
000300745 980__ $$aUNRESTRICTED